Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 24, Issue 14
15 July 2018
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows an ovarian cancer tissue section from a patient harboring a rare PD-L1 tumor genetic rearrangement. Immunofluorescence multiplex imaging demonstrates strong colocalization of PD-L1 and cytokeratin in the tumor cells with negative PD-L1 expression in infiltrating CD68+ macrophages. PD-L1 (red)/cytokeratin (green)/DAPI (blue)/CD68 (magenta). For details, see the article by Bellone and colleagues on page 3282 of this issue.
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Author Choice
Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
Stephanie Lheureux
View articletitled, Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
Open the PDF for in another window
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
Leire Ruiz-Cerdá; Eduardo Asín-Prieto; Zinnia P. Parra-Guillen; Iñaki F. Trocóniz
View articletitled, The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
Open the PDF for in another window
Antigen Presentation Keeps Trending in Immunotherapy Resistance
Anusha Kalbasi; Antoni Ribas
View articletitled, Antigen Presentation Keeps Trending in Immunotherapy Resistance
Open the PDF for in another window

CCR Drug Updates

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Emily Y. Jen; Chia-Wen Ko; Jee Eun Lee; Pedro L. Del Valle; Antonina Aydanian; Charles Jewell; Kelly J. Norsworthy; Donna Przepiorka; Lei Nie; Jiang Liu; Christopher M. Sheth; Marjorie Shapiro; Ann T. Farrell; Richard Pazdur
View articletitled, FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Supplementary data
Open the PDF for in another window

Clinical Trial Brief Report

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
Jorge J. Castillo; Kirsten Meid; Joshua N. Gustine; Toni Dubeau; Patricia Severns; Zachary R. Hunter; Guang Yang; Lian Xu; Steven P. Treon
View articletitled, Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
Open the PDF for in another window

Clinical Trials: Targeted Therapy

Author Choice
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Johanna C. Bendell; Anna M. Varghese; David M. Hyman; Todd M. Bauer; Shubham Pant; Sophie Callies; Ji Lin; Ricardo Martinez; Enaksha Wickremsinhe; Aaron Fink; Volker Wacheck; Kathleen N. Moore
View articletitled, A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Supplementary data
Open the PDF for in another window
Author Choice
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
David S. Hong; Kathleen Moore; Manish Patel; Stefan C. Grant; Howard A. Burris, III; William N. William, Jr; Suzanne Jones; Funda Meric-Bernstam; Jeffrey Infante; Lisa Golden; Wei Zhang; Ricardo Martinez; Sameera Wijayawardana; Richard Beckmann; Aimee Bence Lin; Cathy Eng; Johanna Bendell
View articletitled, Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
Supplementary data
Open the PDF for in another window
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
James P. Dugan; Bradley M. Haverkos; Lynda Villagomez; Ludmila K. Martin; Mark Lustberg; John Patton; Marisa Martin; Ying Huang; Gerard Nuovo; Fengting Yan; Robert Cavaliere; Joyce Fingeroth; Shannon C. Kenney; Richard F. Ambinder; Gerard Lozanski; Pierluigi Porcu; Michael A. Caligiuri; Robert A. Baiocchi
View articletitled, Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
Supplementary data
Open the PDF for in another window

Clinical Trials: Immunotherapy

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Stefania Bellone; Natalia Buza; Jungmin Choi; Luca Zammataro; Laurie Gay; Julia Elvin; David L. Rimm; Yuting Liu; Elena S. Ratner; Peter E. Schwartz; Alessandro D. Santin
View articletitled, Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Supplementary data
Open the PDF for in another window
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Laurent Claret; Jin Y. Jin; Charles Ferté; Helen Winter; Sandhya Girish; Mark Stroh; Pei He; Marcus Ballinger; Alan Sandler; Amita Joshi; Achim Rittmeyer; David Gandara; Jean-Charles Soria; René Bruno
View articletitled, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Supplementary data
Open the PDF for in another window

Precision Medicine and Imaging

Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Zhenqing Ye; Haidong Dong; Ying Li; Tao Ma; Haojie Huang; Hon Sing Leong; Jeanette Eckel-Passow; Jean-Pierre A. Kocher; Han Liang; Liguo Wang
View articletitled, Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Supplementary data
Open the PDF for in another window
A Gallium-67/68–Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake
Tomoya Uehara; Miki Yokoyama; Hiroyuki Suzuki; Hirofumi Hanaoka; Yasushi Arano
View articletitled, A Gallium-67/68–Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake
Supplementary data
Open the PDF for in another window
Author Choice
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Juozas Gordevičius; Algimantas Kriščiūnas; Daniel E. Groot; Steven M. Yip; Miki Susic; Andrew Kwan; Rafal Kustra; Anthony M. Joshua; Kim N. Chi; Art Petronis; Gabriel Oh
View articletitled, Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Supplementary data
Open the PDF for in another window
Author Choice
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Benjamin Ribba; Christophe Boetsch; Tapan Nayak; Hans Peter Grimm; Jehad Charo; Stefan Evers; Christian Klein; Jean Tessier; Jean Eric Charoin; Alex Phipps; Pavel Pisa; Volker Teichgräber
View articletitled, Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Supplementary data
Open the PDF for in another window
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Caroline E. McCoach; Anh T. Le; Katherine Gowan; Kenneth Jones; Laura Schubert; Andrea Doak; Adriana Estrada-Bernal; Kurtis D. Davies; Daniel T. Merrick; Paul A. Bunn, Jr; W. Tom Purcell; Rafal Dziadziuszko; Marileila Varella-Garcia; Dara L. Aisner; D. Ross Camidge; Robert C. Doebele
View articletitled, Resistance Mechanisms to Targeted Therapies in <em>ROS1</em><sup>+</sup> and <em>ALK</em><sup>+</sup> Non–small Cell Lung Cancer
Supplementary data
Open the PDF for in another window
Author Choice
Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S. Rugo; Javier Cortes; Ahmad Awada; Joyce O'Shaughnessy; Chris Twelves; Seock-Ah Im; Alison Hannah; Lin Lu; Sherwin Sy; Katie Caygill; Deborah A. Zajchowski; Darren W. Davis; Mary Tagliaferri; Ute Hoch; Edith A. Perez
View articletitled, Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Supplementary data
Open the PDF for in another window
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Sibylle Loibl; Karsten Weber; Jens Huober; Kristin Krappmann; Frederik Marmé; Christian Schem; Knut Engels; Berit Maria Pfitzner; Sherko Kümmel; Jenny Furlanetto; Arndt Hartmann; Silvia Darb-Esfahani; Volkmar Müller; Annette Staebler; Gunter von Minckwitz; Ralf Kronenwett; Carsten Denkert
View articletitled, Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Supplementary data
Open the PDF for in another window

Translational Cancer Mechanisms and Therapy

Author Choice
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Lu Huang; Shruti Malu; Jodi A. McKenzie; Miles C. Andrews; Amjad H. Talukder; Trang Tieu; Tatiana Karpinets; Cara Haymaker; Marie-Andrée Forget; Leila J. Williams; Zhe Wang; Rina M. Mbofung; Zhi-Qiang Wang; Richard Eric Davis; Roger S. Lo; Jennifer A. Wargo; Michael A. Davies; Chantale Bernatchez; Timothy Heffernan; Rodabe N. Amaria; Anil Korkut; Weiyi Peng; Jason Roszik; Gregory Lizée; Scott E. Woodman; Patrick Hwu
View articletitled, The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Supplementary data
Open the PDF for in another window
Author Choice
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Martina Sanlorenzo; Igor Vujic; Arianna Floris; Mauro Novelli; Loretta Gammaitoni; Lidia Giraudo; Marco Macagno; Valeria Leuci; Ramona Rotolo; Chiara Donini; Marco Basiricò; Pietro Quaglino; Maria Teresa Fierro; Silvia Giordano; Maria Sibilia; Fabrizio Carnevale-Schianca; Massimo Aglietta; Dario Sangiolo
View articletitled, BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Supplementary data
Open the PDF for in another window
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Gheath Alatrash; Alexander A. Perakis; Celine Kerros; Haley L. Peters; Pariya Sukhumalchandra; Mao Zhang; Haroon Jakher; Madhushree Zope; Rebecca Patenia; Anna Sergeeva; Shuhua Yi; Ken H. Young; Anne V. Philips; Amanda M. Cernosek; Haven R. Garber; Na Qiao; Jinsheng Weng; Lisa S. St John; Sijie Lu; Karen Clise-Dwyer; Elizabeth A. Mittendorf; Qing Ma; Jeffrey J. Molldrem
View articletitled, Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Supplementary data
Open the PDF for in another window
Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Annemarie E.M. Post; Marcel Smid; Anika Nagelkerke; John W.M. Martens; Johan Bussink; Fred C.G.J. Sweep; Paul N. Span
View articletitled, Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Supplementary data
Open the PDF for in another window
Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Dipongkor Saha; Hiroaki Wakimoto; Cole W. Peters; Slawomir J. Antoszczyk; Samuel D. Rabkin; Robert L. Martuza
View articletitled, Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Supplementary data
Open the PDF for in another window
Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma
Ying Pang; Yanxin Lu; Veronika Caisova; Yang Liu; Petra Bullova; Thanh-Truc Huynh; Yiqiang Zhou; Di Yu; Zdenek Frysak; Igor Hartmann; David Taïeb; Karel Pacak; Chunzhang Yang
View articletitled, Targeting NAD<sup>+</sup>/PARP DNA Repair Pathway as a Novel Therapeutic Approach to <em>SDHB</em>-Mutated Cluster I Pheochromocytoma and Paraganglioma
Supplementary data
Open the PDF for in another window
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C. West; Masha Kocherginsky; Eva Y. Tonsing-Carter; D. Nesli Dolcen; David J. Hosfield; Ricardo R. Lastra; Jason P. Sinnwell; Kevin J. Thompson; Kathleen R. Bowie; Ryan V. Harkless; Maxwell N. Skor; Charles F. Pierce; Sarah C. Styke; Caroline R. Kim; Larischa de Wet; Geoffrey L. Greene; Judy C. Boughey; Matthew P. Goetz; Krishna R. Kalari; Liewei Wang; Gini F. Fleming; Balázs Györffy; Suzanne D. Conzen
View articletitled, Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Supplementary data
Open the PDF for in another window
A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research
Delphine R. Boulbes; Tracy Costello; Keith Baggerly; Fan Fan; Rui Wang; Rajat Bhattacharya; Xiangcang Ye; Lee M. Ellis
View articletitled, A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research
Supplementary data
Open the PDF for in another window
Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples
Wina Verlaat; Barbara C. Snoek; Daniëlle A.M. Heideman; Saskia M. Wilting; Peter J.F. Snijders; Putri W. Novianti; Annina P. van Splunter; Carel F.W. Peeters; Nienke E. van Trommel; Leon F.A.G. Massuger; Ruud L.M. Bekkers; Willem J.G. Melchers; Folkert J. van Kemenade; Johannes Berkhof; Mark A. van de Wiel; Chris J.L.M. Meijer; Renske D.M. Steenbergen
View articletitled, Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples
Supplementary data
Open the PDF for in another window
Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Lawrence L'Italien; Olivia Orozco; Tinya Abrams; Lisa Cantagallo; Anu Connor; Jayesh Desai; Hilmar Ebersbach; Hans Gelderblom; Keith Hoffmaster; Emma Lees; Heiko Maacke; Siew Schleyer; Darko Skegro; Si Tuen Lee-Hoeflich
View articletitled, Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Supplementary data
Open the PDF for in another window

Advertisement

Breaking
Mammogram Reports Must Now Specify Breast Density
E-cigarette Use Drops Dramatically among Kids
The NCI Calls for $11.446 Billion in Funding for FY 2026
View more recent articles
Latest News
Evidence Points to the Value of Neoadjuvant Therapy for NSCLC
Drug Combo Better than Single Agent in EGFR, MET-Mutated NSCLC
HER2-Targeted Agents Potential First Treatments for NSCLC
View more recent articles
Research Watch
Post-Fast Refeeding Drives Stem Cell Regeneration via Polyamine Metabolism
The Fanconi Anemia Pathway Mediates Chromothripsis and Resistance to Cancer Therapy
X Chromosome Translocations Drive Sex Bias in a Rare Kidney Cancer Subtype
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept